The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients (MAESTRO-NAFLD1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04197479
Recruitment Status : Completed
First Posted : December 13, 2019
Last Update Posted : September 5, 2023
Sponsor:
Information provided by (Responsible Party):
Madrigal Pharmaceuticals, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo. At least 100 patients will be enrolled in a 100 mg open-label arm and will include a special safety population (eg, patients with compensated NASH cirrhosis).

Condition or disease Intervention/treatment Phase
Non-Alcoholic Fatty Liver Disease Drug: Placebo Drug: Resmetirom Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1343 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
Actual Study Start Date : December 16, 2019
Actual Primary Completion Date : January 6, 2023
Actual Study Completion Date : January 6, 2023

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Open label: resmetirom
100 mg daily
 Drug: Resmetirom
Tablet
Other Name: MGL-3196
Placebo Comparator: Double blinded: matching placebo
Placebo daily
 Drug: Placebo
Matching tablets
Experimental: Double blinded: resmetirom 80 mg
80 mg daily
 Drug: Resmetirom
Tablet
Other Name: MGL-3196
Experimental: Double blinded: resmetirom 100 mg
100 mg daily
 Drug: Resmetirom
Tablet
Other Name: MGL-3196


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the incidence of adverse events. [ Time Frame: 52 weeks ]
    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the incidence of adverse events.


Secondary Outcome Measures :
  1. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in low density lipoprotein C (LDL-C) from baseline to Week 24 [ Time Frame: 24 weeks ]
    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in low density lipoprotein C (LDL-C) from baseline to Week 24

  2. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in apolipoprotein B (ApoB) from baseline to Week 24 [ Time Frame: 24 weeks ]
    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in apolipoprotein B (ApoB) from baseline to Week 24

  3. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in hepatic fat fraction as determined by MRI-PDFF from baseline to Week 16. [ Time Frame: 16 weeks ]
    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in hepatic fat fraction as determined by MRI-PDFF from baseline to Week 16.

  4. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in triglycerides (TGs) from baseline to Week 24 in patients with baseline TG > 150 mg/dL. [ Time Frame: 24 weeks ]
    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the percent change in triglycerides (TGs) from baseline to Week 24 in patients with baseline TG > 150 mg/dL.

  5. The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo after 52 weeks on FibroScan controlled attenuation parameter (CAP) [ Time Frame: 52 weeks ]
    The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo after 52 weeks on FibroScan controlled attenuation parameter (CAP)

  6. The change from baseline to Week 52 in FibroScan vibration controlled transient elastography (kPa) [ Time Frame: 52 weeks ]
    The change from baseline to Week 52 in FibroScan vibration controlled transient elastography (VCTE) (kPa) in patients with baseline kPa >/=7.2 and a Week 52 or end of treatment FibroScan (VCTE)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must be willing to participate in the study and provide written informed consent.
  • Male and female adults ≥18 years of age.

  • Suspected or confirmed diagnosis of NASH or NAFLD (presumed NASH):

    • Fibroscan with kPa ≥5.5 and <8.5; CAP ≥280 dB.m-1 OR
    • MRE ≥2 and <4.0; MRI-PDFF ≥8% liver fat consistent with steatosis and fibrosis stage ≥1 and <4. OR

    • Recent liver biopsy (within past 2 years) documenting NASH/NAFLD with steatosis showing one of the following:

      • NAS ≥4, steatosis ≥1, fibrosis stage 0 or F1A/1C with PRO-C3 <14
      • NAS <4, steatosis ≥1, with fibrosis stage ≤3

      • NAS ≥4, steatosis ≥1, fibrosis stage ≤3 without ballooning

        • NOTE: Since the completion of enrollment of the double-blind arms, patients meeting all other criteria who have a liver biopsy result from MGL-3196-11 with the following may be enrolled in the open-label active treatment arm of MGL-3196-14 (100 mg dose):

          • NAS = 3, steatosis 1, ballooning 1, inflammation 1 with F2 or F3
          • NAS = 3, ballooning 0 with F2 or F3
        • For the compensated NASH cirrhosis arm, eligible patients must have compensated NASH cirrhosis diagnosed by liver biopsy showing NASH with F4 stage fibrosis (either historic or recent biopsy) or a historic biopsy with NASH F2-F3 fibrosis with subsequent progression to NASH cirrhosis as diagnosed by an expert hepatologist/gastroenterologist.

    • Compensated NASH cirrhosis at screening and baseline includes

      • Child Pugh-A (score 5-6) ( may have either mild hepatic encephalopathy OR mild diuretic responsive ascites OR albumin < 3.5 and ≥ 3.2 (not any two of these, unless explained by Gilbert's Syndrome or non-hepatic causes)).
      • MELD < 12 at screening/baseline unless MELD ≥ 12 based on non-cirrhotic parameters (e.g., elevated INR due to anticoagulation, bilirubin elevation due to documented Gilbert's Syndrome, elevated creatine due to renal disease (non-hepatic)).
      • Albumin ≥ 3.2.
      • Bilirubin < 2 (unless documented Gilbert's Syndrome).
  • MRI-PDFF fat fraction ≥8% obtained during the Screening Period (baseline MRI-PDFF) or a historic MRI-PDFF ≤8 weeks old at the time of randomization.
  • Stable dyslipidemia therapy for ≥30 days prior to randomization.

Exclusion Criteria:

  • History of significant alcohol consumption for a period of more than 3 consecutive months within 1 year prior to Screening.
  • Regular use of drugs historically associated with NAFLD.
  • History of bariatric surgery or intestinal bypass surgery within the 5 years prior to randomization or planned during the conduct of the study.
  • Weight gain or loss ≥5% total body weight within 12 weeks prior to randomization.
  • HbA1c >9.0%.
  • Glucagon-like peptide 1 [GLP-1] agonist therapy or high dose vitamin E (>400 IU/day) unless stable for 24 weeks prior to biopsy.
  • Presence of cirrhosis on liver biopsy defined as stage 4 fibrosis.
  • Diagnosis of hepatocellular carcinoma (HCC).
  • Model for End-stage Liver Disease (MELD) score ≥12, as determined at Screening, unless due to therapeutic anti coagulation or Gilbert syndrome.
  • Hepatic decompensation.
  • Chronic liver diseases.
  • Has an active autoimmune disease.
  • Serum ALT >250 U/L.
  • History of biliary diversion.
  • Uncontrolled hypertension (either treated or untreated).
  • Active, serious medical disease with a likely life expectancy <2 years.
  • Participation in an investigational new drug trial in the 60 days or 5 half-lives, whichever is longer, prior to randomization.
  • Any other condition which, in the opinion of the Investigator, would impede compliance, hinder completion of the study, compromise the well-being of the patient, or interfere with the study outcomes.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04197479


Locations
Show Show 77 study locations
Sponsors and Collaborators
Madrigal Pharmaceuticals, Inc.
Investigators
Layout table for investigator information
Study Director: Rebecca Taub, MD Madrigal Pharmaceuticals, Inc.
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Madrigal Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT04197479    
Other Study ID Numbers: MGL-3196-14
First Posted: December 13, 2019    Key Record Dates
Last Update Posted: September 5, 2023
Last Verified: August 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Madrigal Pharmaceuticals, Inc.:
NAFLD
NASH
Hyperlipidemia
Resmetirom
Thyroid hormone receptor beta
Hepatic
Fibrosis
 NASH resolution
Thyroid hormone receptor agonist
Cardiovascular
Dyslipidemia
Fatty liver disease
Nonalcoholic steatohepatitis
Cirrhosis
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Digestive System Diseases